Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis
Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis
复制标题
DOI：
10.1002/mds.10118
复制
发表时间：
2002-05-01
影响因子：
8.6
通讯作者：
Frucht, S
中科院分区：
文献类型：
--
作者：
Chatterjee, A;Louis, ED;Frucht, S
抗惊厥药物常用于阵发性运动性舞蹈病(PKC)的治疗。尽管它们在消除阵发性运动方面通常非常有效，但短期和长期的副作用可能会限制年轻患者使用它们。左乙拉西坦(Keppra)是一种新的抗癫痫药物，被批准用于部分性癫痫的治疗，在癫痫患者中耐受性良好。我们报告了左乙拉西坦在PKC治疗中的应用。左乙拉西坦在消除发作事件方面是有效的，应该被认为是LIS标准抗癫痫药物的全部替代药物。(C)2002年行动失调社。
Anticonvulsants are frequently used in the treatment of paroxysmal kinesiogenic choreoathetosis (PKC). Although they are often extremely effective in eliminating paroxysmal movements, short- and long-term side-effects may limit their use ill young patients. Levetiracetam (Keppra), a novel antiepileptic drug approved for the treatment of partial seizures is well tolerated in patients with epilepsy. We report on the use of levetiracetam in the treatment of PKC. Levetiracetam was effective in eliminating paroxysmal events and should be considered Lis all alternative to standard antiepileptic medications in this disorder. (C) 2002 Movement Disorder Society.